Kevin Mclaughlin Biography and Net Worth

Director of Invivyd

Kevin F. McLaughlin has served as a member of our Board since May 2024. Mr. McLaughlin has more than 40 years of financial and operating management experience spanning the biotech, high-tech and education industries. Most notably, from 2010 to 2021, Mr. McLaughlin served as Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma Inc. (Acceleron) until its acquisition by Merck & Co., Inc. At Acceleron, he was a key member of the management team that helped drive the company’s growth from a private research-focused business to a publicly traded commercial entity. Prior to Acceleron, Mr. McLaughlin held several executive leadership roles within different organizations, including serving as the President and Chief Executive Officer and a member of the Board of Directors of PRAECIS Pharmaceuticals Incorporated. Mr. McLaughlin currently serves on the Board of Directors of Vericel Corporation, a publicly-traded leading provider of advanced therapies for the sports medicine and severe burn care markets, and two recently formed private biotech companies. He previously served on the board of directors of Decibel Therapeutics, until its sale to Regeneron Pharmaceuticals, and the Board of Directors of Stealth Biotherapeutics, until it was brought private by a venture firm. Mr. McLaughlin received a B.S. from Northeastern University and an M.B.A. from the F.W. Olin Graduate School of Business at Babson College.

What is Kevin F. Mclaughlin's net worth?: The estimated net worth of Kevin F. Mclaughlin is at least $79.50 thousand as of November 19th, 2025. Mr. Mclaughlin owns 50,000 shares of Invivyd stock worth more than $79,500 as of April 21st. This net worth evaluation does not reflect any other investments that Mr. Mclaughlin may own. Learn More about Kevin F. Mclaughlin's net worth.
How do I contact Kevin F. Mclaughlin?: The corporate mailing address for Mr. Mclaughlin and other Invivyd executives is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. Invivyd can also be reached via phone at 781-819-0080 and via email at [email protected]. Learn More on Kevin F. Mclaughlin's contact information.
Has Kevin F. Mclaughlin been buying or selling shares of Invivyd?: Kevin F. Mclaughlin has not been actively trading shares of Invivyd during the last ninety days. Most recently, on Wednesday, November 19th, Kevin F. Mclaughlin bought 50,000 shares of Invivyd stock. The stock was acquired at an average cost of $2.50 per share, with a total value of $125,000.00. Following the completion of the transaction, the director now directly owns 50,000 shares of the company's stock, valued at $125,000. Learn More on Kevin F. Mclaughlin's trading history.
Who are Invivyd's active insiders?: Invivyd's insider roster includes Robert Allen, III (Chief Scientific Officer), Jill Andersen (Chief Legal Officer & Corporate Secretary), William Duke (Chief Financial Officer), Julie Green (Chief Human Resources Officer), Timothy Lee (Chief Commercial Officer), Terrance McGuire (Director), and Kevin Mclaughlin (Director). Learn More on Invivyd's active insiders.
Are insiders buying or selling shares of Invivyd?: In the last twelve months, Invivyd insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $125,000.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 504,826 shares worth more than $521,748.82. The most recent insider tranaction occured on February, 18th when insider Robert D Allen III sold 19,392 shares worth more than $30,639.36. Insiders at Invivyd own 25.4% of the company. Learn More about insider trades at Invivyd.
Information on this page was last updated on 2/18/2026.

Kevin F. Mclaughlin Insider Trading History at Invivyd

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/19/2025	Buy	50,000	$2.50	$125,000.00	50,000

Kevin F. Mclaughlin Buying and Selling Activity at Invivyd

Invivyd Company Overview

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $1.59

$1.58

$1.69

50 Day Range

MA: $1.59

$1.19

$1.90

2 Week Range

Now: $1.59

$0.48

$3.07

Volume

1,146,624 shs

Average Volume

3,093,435 shs

Market Capitalization

$449.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73